Anna Orlova

10.3k total citations
290 papers, 8.3k citations indexed

About

Anna Orlova is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Anna Orlova has authored 290 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 264 papers in Radiology, Nuclear Medicine and Imaging, 141 papers in Oncology and 70 papers in Molecular Biology. Recurrent topics in Anna Orlova's work include Radiopharmaceutical Chemistry and Applications (213 papers), Monoclonal and Polyclonal Antibodies Research (193 papers) and HER2/EGFR in Cancer Research (93 papers). Anna Orlova is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (213 papers), Monoclonal and Polyclonal Antibodies Research (193 papers) and HER2/EGFR in Cancer Research (93 papers). Anna Orlova collaborates with scholars based in Sweden, Russia and Denmark. Anna Orlova's co-authors include Vladimir Tolmachev, Mattias Sandström, Anders Wennborg, Joachim Feldwisch, Stefan Ståhl, Helena Wållberg, Lars Abrahmsén, Bogdan Mitran, Fredrik Nilsson and Amelie Eriksson Karlström and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biomaterials.

In The Last Decade

Anna Orlova

277 papers receiving 8.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Anna Orlova	6.9k	3.9k	2.8k	1.0k	476	290	8.3k
Vladimir Tolmachev	9.4k 1.4×	4.9k 1.3×	4.0k 1.5×	1.4k 1.4×	593 1.2×	401	11.9k
Guus A.M.S. van Dongen	5.0k 0.7×	2.9k 0.8×	2.4k 0.9×	2.0k 2.0×	310 0.7×	184	8.6k
Roland Haubner	3.8k 0.5×	2.0k 0.5×	2.7k 1.0×	694 0.7×	457 1.0×	93	7.3k
Robert M. Sharkey	8.0k 1.2×	5.4k 1.4×	2.9k 1.1×	2.2k 2.1×	877 1.8×	281	12.1k
Diane E. Milenic	4.4k 0.6×	1.6k 0.4×	1.9k 0.7×	1.0k 1.0×	287 0.6×	113	5.8k
Shuang Liu	4.2k 0.6×	2.0k 0.5×	1.4k 0.5×	1.0k 1.0×	358 0.8×	127	5.9k
David Colcher	6.7k 1.0×	3.2k 0.8×	3.9k 1.4×	980 1.0×	561 1.2×	208	9.9k
Margret Schottelius	3.8k 0.5×	2.4k 0.6×	1.1k 0.4×	2.5k 2.5×	663 1.4×	114	6.1k
Andrew Raubitschek	4.3k 0.6×	4.3k 1.1×	2.7k 1.0×	950 0.9×	310 0.7×	157	9.1k
Edmund A. Rossi	2.9k 0.4×	1.8k 0.5×	1.4k 0.5×	530 0.5×	204 0.4×	85	4.3k

Countries citing papers authored by Anna Orlova

Since Specialization

Citations

This map shows the geographic impact of Anna Orlova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Orlova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Orlova more than expected).

Fields of papers citing papers by Anna Orlova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Orlova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Orlova. The network helps show where Anna Orlova may publish in the future.

Co-authorship network of co-authors of Anna Orlova

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Orlova. A scholar is included among the top collaborators of Anna Orlova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Orlova. Anna Orlova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tzortzakakis, Antonios, Chunde Li, Renske Altena, et al.. (2025). First-in-human experience with GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in prostate and breast cancer patients using PET/CT. EJNMMI Research. 15(1). 12–12. 2 indexed citations

Tolmachev, Vladimir, Anzhelika Vorobyeva, Javad Garousi, et al.. (2025). Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture. International Journal of Molecular Sciences. 26(11). 5236–5236. 1 indexed citations

Abouzayed, Ayman, A Mattsson, Vladimir Tolmachev, et al.. (2024). GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics. Pharmaceutics. 16(4). 513–513. 5 indexed citations

Oroujeni, Maryam, et al.. (2024). Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation. EJNMMI Radiopharmacy and Chemistry. 9(1). 30–30. 2 indexed citations

Baun, Christina, Birgitte Brinkmann Olsen, Carla L. Alves, et al.. (2024). Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: A preclinical study of the theranostic pair [55Co]Co- and [177Lu]Lu-DOTA-RM26. Nuclear Medicine and Biology. 138-139. 108961–108961. 5 indexed citations

Mattsson, A, Ayman Abouzayed, Berthold A. Nock, et al.. (2024). Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI Radiopharmacy and Chemistry. 9(1). 3 indexed citations

Zhang, Jie, Sara S. Rinne, E. Bjorklund, et al.. (2024). Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts. ACS Pharmacology & Translational Science. 7(10). 3228–3240. 2 indexed citations

Xu, Tianqi, et al.. (2023). Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab. Cancers. 15(9). 2409–2409. 13 indexed citations

Rinne, Sara S., Ayman Abouzayed, Anzhelika Vorobyeva, et al.. (2022). Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. Biomedicines. 10(6). 1293–1293. 5 indexed citations

10.

Garousi, Javad, Tianqi Xu, Olga Vorontsova, et al.. (2022). Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart. Pharmaceutics. 14(8). 1612–1612. 3 indexed citations

11.

Vorobyeva, Anzhelika, Leendert J. van den Bos, Robert Naasz, et al.. (2022). Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics. 14(11). 2519–2519. 5 indexed citations

12.

Xu, Tianqi, Jie Zhang, Maryam Oroujeni, et al.. (2022). Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. Pharmaceutics. 14(3). 522–522. 7 indexed citations

13.

Xu, Tianqi, Anna Orlova, Maryam Oroujeni, et al.. (2022). Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics. 14(7). 1475–1475. 7 indexed citations

14.

Garousi, Javad, Tianqi Xu, Anzhelika Vorobyeva, et al.. (2021). Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 13(11). 1847–1847. 8 indexed citations

15.

Xu, Tianqi, Maryam Oroujeni, Jie Zhang, et al.. (2021). The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics. 13(11). 1974–1974. 11 indexed citations

16.

Xu, Tianqi, Jie Zhang, Vladimir Tolmachev, et al.. (2021). Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. Pharmaceutics. 13(3). 430–430. 14 indexed citations

17.

Xu, Tianqi, Anzhelika Vorobyeva, Alexey Schulga, et al.. (2021). Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. Cancers. 13(16). 3939–3939. 11 indexed citations

18.

Xu, Tianqi, Anzhelika Vorobyeva, Maryam Oroujeni, et al.. (2020). Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. Cancers. 13(1). 85–85. 25 indexed citations

19.

Sandin, Linda C., Anna Orlova, Erika Gustafsson, et al.. (2013). Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunology Research. 2(1). 80–90. 81 indexed citations

20.

Xu, Bo, Zohreh Varasteh, Anna Orlova, et al.. (2013). Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochemical and Biophysical Research Communications. 441(4). 820–824. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact